Comment on "the role of naive T cell precursor frequency and recruitment in dictating immune response magnitude"

Journal of Immunology

Volumn 190, Issue 5, 2013, Pages 1895-

  Maillere, Bernard ^a  

^a CEA SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BEVACIZUMAB; ERYTHROPOIETIN; ETANERCEPT; INFLIXIMAB; MELANOMA ANTIGEN 3; NY ESO 1 ANTIGEN; RITUXIMAB; TRASTUZUMAB;

ANEMIA; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LETTER; NONHUMAN; PRE T LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS; HUMANS; IMMUNITY, CELLULAR; PEPTIDES; PRECURSOR CELLS, T-LYMPHOID; RECEPTORS, ANTIGEN, T-CELL;

EID: 84874273302     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1290079     Document Type: Letter

References (9)

1. Jenkins, M. K., and J. J. Moon. 2012. The role of naive T cell precursor frequency and recruitment in dictating immune response magnitude. J. Immunol. 188: 4135-4140.
2. Delluc, S., G. Ravot, and B. Maillere. 2011. Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors. FASEB J. 25: 2040-2048.
3. Delluc, S., G. Ravot, and B. Maillere. 2010. Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential. Blood 116: 4542-4545.
4. Geiger, R., T. Duhen, A. Lanzavecchia, and F. Sallusto. 2009. Human naive and memory CD41 T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells. J. Exp. Med. 206: 1525-1534.
5. Gebel, H. M., J. R. Scott, C. A. Parvin, and G. E. Rodey. 1983. In vitro immunization to KLH. II. Limiting dilution analysis of antigen-reactive cells in primary and secondary culture. J. Immunol. 130: 29-32.
6. Zhang, Y., Z. Sun, H. Nicolay, R. G. Meyer, N. Renkvist, V. Stroobant, J. Corthals, J. Carrasco, A. M. Eggermont, M. Marchand, et al. 2005. Monitoring of antivaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein. J. Immunol. 174: 2404-2411.
7. Valmori, D., N. E. Souleimanian, C. S. Hesdorffer, L. J. Old, and M. Ayyoub. 2005. Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD41 T cells in cancer-free individuals. Clin. Immunol. 117: 161-167.
8. Zhang, Y., N. Renkvist, Z. Sun, B. Schuler-Thurner, N. Glaichenhaus, G. Schuler, T. Boon, P. van der Bruggen, and D. Colau. 2005. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells. Eur. J. Immunol. 35: 1066-1075.
9. Wang, X. F., W. M. Cohen, F. A. Castelli, C. Almunia, B. Lethé, S. Pouvelle- Moratille, G. Munier, D. Charron, A. Ménez, H. M. Zarour, et al. 2007. Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family. Cancer Immunol. Immunother. 56: 807-818.